Inozyme Pharma (INZY) News Today → Read this before you buy AI stocks (From InvestorPlace) (Ad) Free INZY Stock Alerts $4.68 +0.08 (+1.74%) (As of 12:33 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16, 2024 | americanbankingnews.comInozyme Pharma, Inc. (NASDAQ:INZY) Short Interest Up 7.6% in AprilMay 12, 2024 | americanbankingnews.comInozyme Pharma (NASDAQ:INZY) Rating Reiterated by Needham & Company LLCMay 11, 2024 | americanbankingnews.comWedbush Research Analysts Lift Earnings Estimates for Inozyme Pharma, Inc. (NASDAQ:INZY)May 11, 2024 | americanbankingnews.comQ2 2024 Earnings Forecast for Inozyme Pharma, Inc. Issued By HC Wainwright (NASDAQ:INZY)May 10, 2024 | marketbeat.comHC Wainwright Research Analysts Reduce Earnings Estimates for Inozyme Pharma, Inc. (NASDAQ:INZY)Inozyme Pharma, Inc. (NASDAQ:INZY - Free Report) - Analysts at HC Wainwright lowered their Q2 2024 EPS estimates for Inozyme Pharma in a note issued to investors on Wednesday, May 8th. HC Wainwright analyst E. White now anticipates that the company will post earnings per share of ($0.39) for theMay 10, 2024 | americanbankingnews.comInozyme Pharma, Inc. (NASDAQ:INZY) Expected to Earn Q1 2025 Earnings of ($0.46) Per ShareMay 9, 2024 | marketbeat.comEquities Analysts Offer Predictions for Inozyme Pharma, Inc.'s Q1 2025 Earnings (NASDAQ:INZY)Inozyme Pharma, Inc. (NASDAQ:INZY - Free Report) - Wedbush issued their Q1 2025 earnings per share (EPS) estimates for Inozyme Pharma in a note issued to investors on Tuesday, May 7th. Wedbush analyst D. Nierengarten forecasts that the company will post earnings per share of ($0.46) for the quartMay 8, 2024 | finanznachrichten.deInozyme Pharma Inc.: Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business HighlightsMay 8, 2024 | msn.comInozyme Pharma GAAP EPS of -$0.38 beats by $0.02May 8, 2024 | markets.businessinsider.comInozyme Pharma Buy Rating Affirmed on Strong Trial Results and Robust Pipeline ProspectsMay 8, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Inozyme Pharma (INZY), Esperion (ESPR) and Madrigal Pharmaceuticals (MDGL)May 8, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT) and Inozyme Pharma (INZY)May 8, 2024 | globenewswire.comInozyme Pharma to Participate at the Bank of America Securities 2024 Health Care ConferenceMay 7, 2024 | marketbeat.comInozyme Pharma's (INZY) Outperform Rating Reaffirmed at WedbushWedbush reiterated an "outperform" rating and set a $15.00 price target on shares of Inozyme Pharma in a report on Tuesday.May 7, 2024 | investorplace.comINZY Stock Earnings: Inozyme Pharma Misses EPS for Q1 2024May 7, 2024 | globenewswire.comInozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business HighlightsMay 3, 2024 | globenewswire.comInozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 9, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Inozyme Pharma (INZY), Moderna (MRNA)April 9, 2024 | marketbeat.comBank of America Lowers Inozyme Pharma (NASDAQ:INZY) Price Target to $14.00Bank of America decreased their price objective on Inozyme Pharma from $16.00 to $14.00 and set a "buy" rating on the stock in a report on Tuesday.April 9, 2024 | marketbeat.comNeedham & Company LLC Reaffirms "Buy" Rating for Inozyme Pharma (NASDAQ:INZY)Needham & Company LLC reiterated a "buy" rating and issued a $23.00 target price on shares of Inozyme Pharma in a research note on Tuesday.April 8, 2024 | marketbeat.comInozyme Pharma's (INZY) "Outperform" Rating Reaffirmed at WedbushWedbush reiterated an "outperform" rating and set a $15.00 price objective on shares of Inozyme Pharma in a research note on Monday.April 8, 2024 | markets.businessinsider.comInozyme Reports Positive Topline Data From Phase 1/2 Study Of INZ-701; Stock UpApril 8, 2024 | globenewswire.comInozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 DeficiencyApril 5, 2024 | globenewswire.comInozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 4, 2024 | insidertrades.comInozyme Pharma, Inc. (NASDAQ:INZY) CEO Douglas A. Treco Sells 7,523 SharesApril 2, 2024 | globenewswire.comInozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare ConferenceMarch 26, 2024 | globenewswire.comInozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024March 15, 2024 | marketbeat.comFY2024 EPS Estimates for Inozyme Pharma, Inc. Lowered by Analyst (NASDAQ:INZY)Inozyme Pharma, Inc. (NASDAQ:INZY - Free Report) - Investment analysts at HC Wainwright cut their FY2024 earnings estimates for Inozyme Pharma in a research report issued on Wednesday, March 13th. HC Wainwright analyst E. White now expects that the company will earn ($1.53) per share for the yearMarch 14, 2024 | marketbeat.comInozyme Pharma, Inc. (NASDAQ:INZY) to Post Q1 2024 Earnings of ($0.35) Per Share, HC Wainwright ForecastsInozyme Pharma, Inc. (NASDAQ:INZY - Free Report) - Research analysts at HC Wainwright issued their Q1 2024 earnings per share estimates for shares of Inozyme Pharma in a research report issued to clients and investors on Wednesday, March 13th. HC Wainwright analyst E. White expects that the compaMarch 13, 2024 | markets.businessinsider.comBuy Rating for Inozyme Pharma Backed by Promising Clinical Progress and Unique Market Positioning of INZ-701March 12, 2024 | benzinga.comInozyme Pharma: Q4 Earnings InsightsMarch 12, 2024 | benzinga.comInozyme Pharma: Q4 Earnings InsightsMarch 12, 2024 | markets.businessinsider.comBuy Rating Affirmed for Inozyme Pharma as Phase I/II Trial Updates and Strong Cash Position Bolster ConfidenceMarch 12, 2024 | markets.businessinsider.comBuy Rating Affirmed for Inozyme Pharma as Phase I/II Trial Updates and Strong Cash Position Bolster ConfidenceMarch 12, 2024 | markets.businessinsider.comInozyme Pharma: Strong Buy Rating Amidst Promising Trial Developments and Market UnderappreciationMarch 12, 2024 | marketbeat.comInozyme Pharma (NASDAQ:INZY) Stock Rating Reaffirmed by WedbushWedbush reaffirmed an "outperform" rating and issued a $15.00 price target on shares of Inozyme Pharma in a research note on Tuesday.March 12, 2024 | finanznachrichten.deInozyme Pharma Inc.: Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business HighlightsMarch 12, 2024 | globenewswire.comInozyme Pharma Reports Full Year 2023 Financial Results and Provides Business HighlightsMarch 10, 2024 | marketbeat.comInozyme Pharma, Inc. (NASDAQ:INZY) Shares Purchased by Schonfeld Strategic Advisors LLCSchonfeld Strategic Advisors LLC boosted its position in Inozyme Pharma, Inc. (NASDAQ:INZY - Free Report) by 346.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 311,880 shares of the company'sMarch 8, 2024 | marketbeat.comFmr LLC Increases Stake in Inozyme Pharma, Inc. (NASDAQ:INZY)Fmr LLC boosted its stake in shares of Inozyme Pharma, Inc. (NASDAQ:INZY - Free Report) by 229.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,465,232 shares of the company's stock after aMarch 7, 2024 | marketbeat.comAdage Capital Partners GP L.L.C. Acquires 1,287,500 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY)Adage Capital Partners GP L.L.C. lifted its position in shares of Inozyme Pharma, Inc. (NASDAQ:INZY - Free Report) by 30.3% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 5,537,500 shares of the company's stock after acquiring an additional 1,287,500 sharesMarch 5, 2024 | marketbeat.comInozyme Pharma, Inc. (NASDAQ:INZY) Shares Purchased by Rock Springs Capital Management LPRock Springs Capital Management LP boosted its position in Inozyme Pharma, Inc. (NASDAQ:INZY - Free Report) by 7.4% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,681,174 shares of the company's stock after purchasinMarch 1, 2024 | marketbeat.comEventide Asset Management LLC Makes New Investment in Inozyme Pharma, Inc. (NASDAQ:INZY)Eventide Asset Management LLC purchased a new position in shares of Inozyme Pharma, Inc. (NASDAQ:INZY - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 3,125,000 shares of the company'sFebruary 26, 2024 | globenewswire.comInozyme Pharma to Participate in the TD Cowen 44th Annual Health Care ConferenceFebruary 25, 2024 | finance.yahoo.comINZY May 2024 5.000 putFebruary 24, 2024 | benzinga.comInozyme Pharma Stock (NASDAQ:INZY), Short Interest ReportFebruary 22, 2024 | benzinga.comBakker Juliet Tammenoms's Net WorthJanuary 30, 2024 | finance.yahoo.comInozyme Pharma, Inc. (INZY)January 19, 2024 | morningstar.comInozyme Pharma Inc Ordinary Shares INZYDecember 21, 2023 | finance.yahoo.comInstitutional investors own a significant stake of 45% in Inozyme Pharma, Inc. (NASDAQ:INZY) Get Inozyme Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for INZY and its competitors with MarketBeat's FREE daily newsletter. Email Address Everybody laughed when he recommended Netflix (Ad)"This Could be Worth Even More than A.I." Whitney Tilson's nailed many of the most famous stocks of the last 25 years – including Netflix, Amazon, and Apple. Now he's pounding the table on a new technology rolling out across America, which early estimates say could create more wealth than A.I., the personal computer, and the smartphone combined. Click here to see how it could become the No. 1 investment of the next decade. INZY Media Mentions By Week INZY Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. INZY News Sentiment▼0.310.42▲Average Medical News Sentiment INZY News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. INZY Articles This Week▼21▲INZY Articles Average Week Get Inozyme Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for INZY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Neoleukin Therapeutics News Aquestive Therapeutics News Rani Therapeutics News Enanta Pharmaceuticals News Xeris Biopharma News CorMedix News Ventyx Biosciences News MacroGenics News Nature's Sunshine Products News 23andMe News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:INZY) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldDoes this make you sick?Allegiance GoldThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Star**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Huge Alerts Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inozyme Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
